COST-EFFECTIVENESS ANALYSIS OF SOCAZOLIMAB IN ADVANCED SMALL-CELL LUNG CANCER...
Author(s)
KUWAHARA KAZUTO, MS1, Mao Yamaguchi, PhD2, Ryutaro Sakai, PhD3, Seiya Taniguchi, PhD3, Kensuke Moriwaki, BS, MS, PhD4.
1Ritsumeikan University, kusatsu, Japan, 2Ritsumeikan university, Kusatsu, Japan, 3Ritsumeikan University, Kusatsu, Japan, 4Ritsumeikan University, Kyoto, Japan.
1Ritsumeikan University, kusatsu, Japan, 2Ritsumeikan university, Kusatsu, Japan, 3Ritsumeikan University, Kusatsu, Japan, 4Ritsumeikan University, Kyoto, Japan.
OBJECTIVES: Advanced small-cell lung cancer (SCLC) is an aggressive malignancy with rapid progression, high recurrence, and poor prognosis. Although immune checkpoint inhibitors have improved outcomes, their high cost raises concerns regarding cost-effectiveness in Japan. This study evaluated the cost-effectiveness of socazolimab for advanced SCLC from the public healthcare payer perspective in Japan.
METHODS: A partitioned survival analysis model was developed using Phase III trial data (NCT04878016) to estimate costs and quality-adjusted life years (QALYs). As the drug price of socazolimab is not established in Japan, it was based on atezolizumab (445,699 JPY/month). Other costs were estimated using the JMDC database. A lifetime horizon and a 2% annual discount rate were applied. Utility values were derived from previous studies. The incremental cost-effectiveness ratio (ICER) was calculated, and sensitivity analyses were conducted.
RESULTS: Socazolimab increased costs by 7,191,031 JPY and gained 0.19 QALYs versus chemotherapy, resulting in an ICER of 37,085,222 JPY/QALY. Sensitivity analyses showed results were most influenced by progression-free utility values. The ICER remained above the 15 million JPY/QALY threshold, with a 0% probability of cost-effectiveness. A 36% price reduction was required to meet the threshold.
CONCLUSIONS: Socazolimab was not cost-effective under current assumptions, highlighting the need to consider cost-effectiveness in pricing and policy decisions.
METHODS: A partitioned survival analysis model was developed using Phase III trial data (NCT04878016) to estimate costs and quality-adjusted life years (QALYs). As the drug price of socazolimab is not established in Japan, it was based on atezolizumab (445,699 JPY/month). Other costs were estimated using the JMDC database. A lifetime horizon and a 2% annual discount rate were applied. Utility values were derived from previous studies. The incremental cost-effectiveness ratio (ICER) was calculated, and sensitivity analyses were conducted.
RESULTS: Socazolimab increased costs by 7,191,031 JPY and gained 0.19 QALYs versus chemotherapy, resulting in an ICER of 37,085,222 JPY/QALY. Sensitivity analyses showed results were most influenced by progression-free utility values. The ICER remained above the 15 million JPY/QALY threshold, with a 0% probability of cost-effectiveness. A 36% price reduction was required to meet the threshold.
CONCLUSIONS: Socazolimab was not cost-effective under current assumptions, highlighting the need to consider cost-effectiveness in pricing and policy decisions.
Conference/Value in Health Info
2026-09, ISPOR Asia Pacific 2026, Bangkok, Thailand
Value in Health, Volume 55, Issue S1
Code
EE101
Topic
Economic Evaluation
Disease
SDC: Oncology